We also show that ER+ BC cells, resistant to endocrine therapy, are enriched in cells expressing BC stemness markers, including MYC. These refractory cells likely upregulate DNA-damage repair genes, whose targeting by dinaciclib alone was not sufficient to counteract the cell growth [42]. The gene discussed is MYC; the disease is breast cancer.